Up­dat­ed: In an­oth­er blow for NASH, FDA ad­comm op­pos­es ac­cel­er­at­ed ap­proval of In­ter­cept drug

An FDA ad­vi­so­ry com­mit­tee on Fri­day vot­ed against rec­om­mend­ing ac­cel­er­at­ed ap­proval of In­ter­cept’s once-re­ject­ed NASH hope­ful obeti­cholic acid, say­ing the risk-ben­e­fit pro­file didn’t stack up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER